Welcome to our dedicated page for Inmune Bio SEC filings (Ticker: INMB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading INmune Bio’s SEC documents often means decoding dense science, shifting clinical timelines, and dozens of risk factors spread across 200-plus pages. If you are hunting for R&D burn rates or trying to spot when executives file Form 4 insider transactions, the traditional EDGAR interface can feel overwhelming.
Stock Titan solves that problem. Our platform delivers AI-powered summaries that turn every filing—from the annual report 10-K to the latest 8-K material event—into plain English. Real-time alerts ensure you see INmune Bio Form 4 insider transactions in real-time the moment they hit the tape, while side-by-side views compare sequential quarters to highlight trial-related spending shifts inside the INmune Bio quarterly earnings report 10-Q filing.
Wondering what to focus on? Investors often use our tools to:
- Track executive stock transactions and cash raises noted in INmune Bio executive stock transactions Form 4
- Analyze pipeline disclosures through an INmune Bio earnings report filing analysis
- Review board pay details in the INmune Bio proxy statement executive compensation
- Monitor trial data releases via INmune Bio 8-K material events explained
Every filing type—S-3 shelves for future capital, S-8 equity plans, or DEF 14A proxy statements—is captured automatically and paired with concise AI commentary so you spend minutes, not hours, understanding INmune Bio SEC documents with AI. If you need the full text, it is one click away, but our synthesized highlights pinpoint the sections that drive valuation for a clinical-stage biotech whose success hinges on data and capital.
Stop searching multiple sources: get INmune Bio SEC filings explained simply with Stock Titan’s complete, constantly updated archive.
INmune Bio (INMB) called a virtual special meeting on November 18, 2025 to seek stockholder approval to reprice certain outstanding stock options. The plan would reset the exercise price of eligible options granted between January 1, 2018 and January 22, 2025 to the closing price of the Company’s common stock on the meeting date, with all other terms (vesting and expiration) unchanged.
The Board cites retention and alignment as key reasons. As of September 30, 2025, the stock closed at $2.07 per share, leaving 100% of options under the 2017, 2019 and 2021 plans underwater. Group-level eligibility includes 2,647,000 options for current executive officers as a group, 1,356,000 for non‑employee directors as a group, and 1,508,000 for non‑executive employees as a group. A separate proposal would allow adjournment to solicit additional proxies if needed. Stockholders of record at close of business on September 30, 2025 (26,585,258 shares outstanding) may vote.
INmune Bio reported that CEO David Moss will participate in a Dermatologic Rare Disease Panel at the Maxim Growth Summit presented by Maxim Group LLC. The event takes place at the Hard Rock Hotel in New York City on October 22–23, 2025.
The company furnished a related press release dated October 14, 2025 as Exhibit 99.1 under Item 8.01.
INmune Bio, Inc. filed a Preliminary Proxy Statement for a 2025 Special Meeting to seek stockholder approval of two proposals: Proposal 1 to reprice certain outstanding stock options and Proposal 2 to adjourn the Special Meeting if necessary. The company will mail and post the Proxy Materials and allow virtual attendance; voting by Internet, telephone or proxy card is available and votes by mail must be received by November 17, 2025. The statement explains that underwater options reduce incentive value and that the Board believes repricing may help retain and motivate employees, officers and directors. The company discloses formulas for accounting under FASB ASC Topic 718 (recognize original grant fair value plus incremental fair value) and summarizes U.S. tax consequences for incentive and nonqualified options. Beneficial ownership disclosures show significant option and warrant holdings, including 1,174,549 option shares exercisable within 60 days for one holder and other named officers with option positions reported as of September 30, 2025.
INmune Bio (INMB) Form 3: Cory Randall Ellspermann, listed as a director and Interim CFO, reported beneficial ownership of stock options totaling 245,000 shares. The filing lists five option grants exercisable on dates between 11/24/2029 and 12/04/2034 with exercise prices from $3.91 to $21.06. One option is noted as fully vested and other grants include stated vesting schedules.
Highbridge Capital Management, LLC reported beneficial ownership of 1,454,400 shares of Inmune Bio, Inc. common stock that are issuable upon exercise of warrants. That amount represents 5.2% of the company's outstanding common stock on a base of 26,585,258 shares as stated in the issuer's prospectus, and the filing clarifies these shares are held by Highbridge-managed funds. The filing identifies Highbridge as a Delaware investment adviser and reports sole voting and dispositive power over the 1,454,400 shares. The statement asserts the securities were acquired in the ordinary course of business and not for the purpose of influencing control.
INmune Bio Inc. disclosure shows two reporting persons—CVI Investments, Inc. and its investment manager Heights Capital Management, Inc.—beneficially hold 1,396,279 shares represented by warrants. Those shares equal 4.9% of the outstanding common stock based on 26,585,258 shares reported outstanding as of June 30, 2025. The warrants include an anti-exercise limitation that prevents exercise to the extent ownership would exceed 4.99%.
The filing states neither reporting person has sole voting or dispositive power; voting and disposition are shared. Heights serves as investment manager to CVI and may exercise voting and dispositive power over the shares held by CVI, while each party disclaims beneficial ownership except for pecuniary interest.
Inmune Bio's Schedule 13G/A shows Praetorian-related entities holding disclosed positions in the company's common stock. Praetorian Capital Fund LLC directly beneficially owns 771,200 shares—comprised of 180,800 shares issuable upon warrants and 590,400 shares underlying call options exercisable within 60 days—representing approximately 2.9% of the class based on 26,585,258 shares outstanding. Mongolia (Barbados) Corp. directly owns 150,000 shares underlying call options (about 0.6%), and Harris Kupperman may be deemed to beneficially own a combined 921,200 shares (about 3.4%).
The filing identifies the reporting persons' roles (investment manager, manager, controlling person) and disclaims beneficial ownership beyond direct holdings. It specifies that reported positions include instruments exercisable within 60 days and includes a certification that the securities were not acquired to change or influence control of the issuer.
FAQ
What is the current stock price of Inmune Bio (INMB)?
What is the market cap of Inmune Bio (INMB)?
